Oncopeptides | Sustainability Performance
Oncopeptides AB focuses on developing peptide-targeted therapies for treating cancer, primarily dedicated to researching and producing innovative medical solutions for oncological disorders.
2003
Sweden
51 - 200 employees
Pharmaceuticals
$1M - 10M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#10639
Overall#436
in Sweden#255
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- Oncopeptides voluntarily withdrew its melflufen cancer drug from the US market in 2021 after a confirmatory trial showed an overall survival detriment.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$7.2MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
139.4%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-331.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 19.5%
0.0
▼ 6.7%
0.0
▼ 9.5%
0.7
2029Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
30%
Independent Directors
3 out of 10 incl. management
Overall score
65
Environment
18
Social
99
Governance
78
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
